The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis
Open accessAbstract
INTRODUCTION: New hepatitis C virus (HCV) medicines have markedly improved treatment efficacy and regimen tolerability. However, their high prices have limited access, prompting wide debate about fair and affordable prices. This study systematically compared the price and affordability of sofosbuvir and ledipasvir/sofosbuvir across 30 countries to assess affordability to health systems and patients. METHODS AND FINDINGS: Published 2015 ex-factory prices for a 12-wk course of treatment were provided by the Pharma Price Information (PPI) service of the Austrian public health institute Gesundheit Österreich GmbH or were obtained from national government or drug reimbursement authorities and recent press releases, where necessary. Prices in Organisation for Economic Co-operation and Development (OECD) member countries and select low- and middle-income countries were converted to US dollars using period average exchange rates and were adjusted for purchasing power parity (PPP). We analysed prices compared to national economic performance and estimated market size and the cost of these drugs in terms of countries' annual total pharmaceutical expenditure (TPE) and in terms of the duration of time an individual would need to work to pay for treatment out of pocket. Patient affordability was calculated using 2014 OECD average annual wages, supplemented with International Labour Organization median wage data where necessary. All data were compiled between 17 July 2015 and 25 January 2016. For the base case analysis, we assumed a 23% rebate/discount on the published price in all countries, except for countries with special pricing arrangements or generic licensing agreements. The median nominal ex-factory price of a 12-wk course of sofosbuvir across 26 OECD countries was US$42,017, ranging from US$37,729 in Japan to US$64,680 in the US. Central and Eastern European countries had higher PPP-adjusted prices than other countries: prices of sofosbuvir in Poland and Turkey (PPP$101,063 and PPP$70,331) and of ledipasvir/sofosbuvir in Poland (PPP$118,754) were at least 1.09 and 1.63 times higher, respectively than in the US (PPP$64,680 and PPP$72,765). Based on PPP-adjusted TPE and without the cost of ribavirin and other treatment costs, treating the entire HCV viraemic population with these regimens at the PPP-adjusted prices with a 23% price reduction would amount to at least one-tenth of current TPE across the countries included in this study, ranging from 10.5% of TPE in the Netherlands to 190.5% of TPE in Poland. In 12 countries, the price of a course of sofosbuvir without other costs was equivalent to 1 y or more of the average annual wage of individuals, ranging from 0.21 y in Egypt to 5.28 y in Turkey. This analysis relies on the accuracy of price information and infection prevalence estimates. It does not include the costs of diagnostic testing, supplementary treatments, treatment for patients with reinfection or cirrhosis, or associated health service costs. CONCLUSIONS: Current prices of these medicines are variable and unaffordable globally. These prices threaten the sustainability of health systems in many countries and prevent large-scale provision of treatment. Stakeholders should implement a fairer pricing framework to deliver lower prices that take account of affordability. Without lower prices, countries are unlikely to be able to increase investment to minimise the burden of hepatitis C.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Awais, A. (2015) · Data Archiving and Networked Services (DANS) · doi:10.17632/zcvgc6m58h.1 · Cited by 6,707
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
International Labour Organization
(2022) · Permanent Missions to the United Nations · doi:10.18356/9789210018289c229 · Cited by 4,331
Global epidemiology and genotype distribution of the hepatitis C virus infection
Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., & Razavi, H. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.027 · Cited by 1,903
Evolving epidemiology of hepatitis C virus
Lavanchy, D. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03432.x · Cited by 1,318
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Afdhal, N., Reddy, K. R., Nelson, D. R., Lawitz, E., Gordon, S. C., Schiff, E., Nahass, R., Ghalib, R., Gitlin, N., Herring, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316366 · Cited by 1,307
Cameron, A., Ewen, M., Ross-Degnan, D., Ball, D., & Laing, R. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61762-6 · Cited by 928
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Zeuzem, S., Dusheiko, G. M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R. H., Illeperuma, A., Svarovskaia, E., Brainard, D. M., Symonds, W. T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316145 · Cited by 795
Bank, W. (2015) · The World Bank Group A to Z 2016 · doi:10.1596/978-1-4648-0484-7_world_development_indicators · Cited by 761
Cited by
Cost–effectiveness thresholds: pros and cons
Bertram, M., Lauer, J., De Joncheere, K., Edejer, T., Hutubessy, R., Kieny, M.-P., & Hill, S. (2016) · Bulletin of the World Health Organization · doi:10.2471/blt.15.164418 · Cited by 783
Self-citationEssential medicines for universal health coverage
Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31599-9 · Cited by 661
Karlsen, T. H., Sheron, N., Zelber-Sagi, S., Carrieri, P., Dusheiko, G., Bugianesi, E., Pryke, R., Hutchinson, S. J., Sangro, B., Martin, N. K., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01701-3 · Cited by 652
Assetization: Turning Things into Assets in Technoscientific Capitalism
(2020) · The MIT Press eBooks · doi:10.7551/mitpress/12075.001.0001 · Cited by 421
Spearman, C. W., Dusheiko, G. M., Hellard, M., & Sonderup, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32320-7 · Cited by 404
Metadata
- Authors
- Iyengar, S., Tay-Teo, K., Vogler, S., Beyer, P., Wiktor, S., de Joncheere, K., & Hill, S.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-05-31
- Volume
- 13
- Issue
- 5
- Pages
- e1002032
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2416145228
- Cited by
- 255
- References
- 31
- FWCI
- 90.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. https://app.cochat.ai/papers/10.1371/journal.pmed.1002032
- The paper
- Iyengar, S., Tay-Teo, K., Vogler, S., Beyer, P., Wiktor, S., de Joncheere, K., & Hill, S. (2016). Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1002032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.